J A Kemp

We are one of the largest UK and European Patent and Trade Mark Attorney firms, with offices in London, Oxford, Cambridge and Munich.

The breadth and depth of our technical knowledge relevant to patents is outstanding, with over 50 science and technology graduates in the firm including over 30 PhDs. No area of science or technology is outside our scope.

Company Type
Twitter Account
@J_A_Kemp
News Page URL
Click here

Karma Oncology

Karma Oncology is a specialist oncology clinical development company headquartered in Scotland with offices in Ireland, Netherlands and USA.  We offer a complete range of development services from clinical development planning, protocol design and authoring, strategic country/site selection, regulatory submissions, through to clinical trial execution and reporting. 

With Karma, experience makes the difference - Our team has successfully completed programs in a broad range of solid tumour and hematologic indications utilizing an array of different therapeutic approaches including immunotherapy and autologous cell therapy and CAR-T cell therapy.

Karma is flexible - We can provide selected individual services, and extend to full-service global CRO capabilities as the program needs expand.  Our size allows us to be flexible, innovative and responsive to individual sponsor requirements and to adhere strictly to specified development timelines.

Karma is different - Our Project Managers have extensive oncology experience, our monitors are professional, mature 'career' CRAs - not trainees - and we have the lowest staff turnover in the industry (<5%).  Many of our staff come from a nursing or medical background, and for international studies we use CRAs native to their country.

Company Type
Twitter Account
@KarmaOncology
News Page URL
Click here

LabGenius

LabGenius is the first biopharmaceutical company developing next generation protein therapeutics using a machine learning-driven evolution engine (EVA) ™.

Our protein engineering platform integrates several bleeding edge technologies from the fields of machine learning, synthetic biology, and robotics. We use advanced deep-learning neural networks to explore protein fitness landscapes and improve multiple drug properties simultaneously.

We are a London-based, privately-owned company, backed by top-tier venture capital funds.

Company Type
Twitter Account
@labgeni_us
News Page URL
Click here

Masters Speciality Pharma

Founded over 30 years ago, Masters Speciality Pharma is an international pharmaceutical company specialising in the distribution of unlicensed medicinal products to Physicians, Hospitals, Clinics, Government institutions and individual patients, providing access to essential life-saving treatments worldwide.

Masters is fully compliant with regulatory requirements in all jurisdictions enabling us to deliver tailored medical solutions to over 90 countries worldwide, and is trusted as a reliable source of pharmaceutical product

Company Type
Twitter Account
N/A
News Page URL
Click here

Medherant

Medherant is developing a pipeline of products for pain and neurology indications, based on our next-generation TEPI-Patch® transdermal drug technology. Our first product – Ibuprofen TEPI Patch – entered the clinic in 2018.

Key advantages of the TEPI Patch® technology over current technologies are the high payload and very efficient release of drug.  This enables lower potency drugs to be formulated as a patch and provides the opportunity to increase the dose of drugs already administered via a patch whilst also minimising the residual drug after use.  

The TEPI Patch® also provides a better experience for the user as it does not leave a residue around the patch – referred to as ‘cold flow’ – and has excellent adhesion whilst still being easy and painless to remove. No organic solvents are involved in this drug-in-adhesive system.

As well as developing our own products, Medherant offers pharma companies rapid feasibility studies using our proprietary high throughput permeation study system to develop transdermal formulations of their drugs of interest.

Company Type
Twitter Account
@medherant
News Page URL
Click here

MediWales

MediWales is the life science network and representative body for Wales.
An independent, not-for-profit organisation that is owned by its members, MediWales provides advice, support, business opportunities and promotes collaborations for the life science and health technology community in Wales.

MediWales delivers an extensive events programme, including the UK HealthTech conference and the MediWales Innovation Awards and produces a number of publications including UK Lifescience Industry magazine, the Annual Directory and Review, and case study magazine LifeStories. MediWales promotes and supports its members in Wales, across the UK and internationally. 

Company Type
Twitter Account
@mediwales
News Page URL
Click here

metaLinear

metaLinear offers a fast track to highly validated drug targets and lead compounds, some of which will be available for licensing. Our focus is on antibiotics/antibiotic resistance. Our proven technology manipulates proteins inside living cells, reaching the >90% of biology inaccessible to siRNA or CAS/Crispr.

metaLinear was established in November 2016 and began operating from the Biohub at Alderley Park in Cheshire from March 2017. Operated by life science incubation specialist, The BioCity Group, Biohub supports the creation and growth of successful life science companies including Redx, Blueberry Therapeutics and the Anti-Microbial Research Centre.

Company Type
Twitter Account
N/A
News Page URL
Click here

MGB Biopharma

MGB Biopharma is a private company based in Glasgow, Scotland and is backed by a syndicate of Scotland’s leading angel investor groups together with Scottish Enterprise. Antimicrobial drug resistance is recognised as a global public health concern with an urgent need for new antibacterial drug classes that are more effective than existing treatments. MGB is developing the first truly novel class of anti-infectives in over a decade that has the potential to treat infections of a number of the most important susceptible and resistant pathogens.

Our lead compound has shown strong bactericidal activity with quick onset of action against many strains of Gram-positive bacteria. It has completed pre-clinical development and progress into our phase 1 clinical study for the treatment of Clostridium difficile have been endorsed by the MHRA. Optimisation of a new formulation for intravenous administration and treatment of systemic Gram-positive infection is ongoing.

MGB has acquired exclusive rights to the proprietary minor groove binder platform, developed at the University of Strathclyde, Glasgow. This platform provides an opportunity to develop additional compounds with the potential to treat Gram-negative, viral, fungal and parasitic infections. MGB continues to work closely with Strathclyde University to develop the pipeline and is currently seeking partners to help maximise the value-creating opportunities from its broad platform.

Twitter Account
@MGB_Biopharma
News Page URL
Click here

Mironid

Mironid is an innovative drug discovery company that develops proprietary drug candidate molecules by modulating the activity of key cell signaling proteins. 

Company Type
Twitter Account
@mironidltd
News Page URL
Click here

OFX

OFX is a global company that provides international money transfers at competitive exchange rates for both businesses and consumers. It offers fee-free transactions, 24/7 customer service and rapid round-the-clock transfers thanks to its unique ‘follow-the-sun’ service model.

Company Type
Twitter Account
@OFX
News Page URL
Click here